Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 2, 2026, Regeneron Pharmaceuticals, Inc. (REGN) has a Wall Street consensus price target of $857.17, based on estimates from 48 covering analysts. With the stock currently trading at $781.67, this represents a potential upside of +9.7%. The company has a market capitalization of $107.56B.
Analyst price targets range from a low of $700.00 to a high of $1057.00, representing a 42% spread in expectations. The median target of $867.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 34 analysts rating the stock as a Buy or Strong Buy,14 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, REGN trades at a trailing P/E of 18.8x and forward P/E of 17.3x. The forward PEG ratio of 2.73 reflects a premium valuation. Analysts expect EPS to grow +8.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $964.14, with bear and bull scenarios of $608.52 and $2305.80 respectively. Model confidence stands at 58/100, reflecting moderate uncertainty in projections.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how REGN stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus price target for REGN is $857.17, close to the current price of $781.67 (9.7% implied move). Based on 48 analyst estimates, the stock appears fairly valued near current levels.
REGN has a consensus rating of "Buy" based on 48 Wall Street analysts. The rating breakdown is predominantly bullish, with 34 Buy/Strong Buy ratings. The consensus 12-month price target of $857.17 implies 9.7% upside from current levels.
With a forward P/E of 17.2514x, REGN trades at a relatively low valuation. The consensus target of $857.17 implies 9.7% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $1057 for REGN, while the most conservative target is $700. The consensus of $857.17 represents the median expectation. Our quantitative valuation model projects a bull case target of $2306 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
REGN is heavily covered by Wall Street, with 48 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 34 have Buy ratings, 14 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month REGN stock forecast based on 48 Wall Street analysts shows a consensus price target of $857.17, with estimates ranging from $700 (bear case) to $1057 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $964, with bear/bull scenarios of $609/$2306.
Our quantitative valuation model calculates REGN's fair value at $964 (base case), with a bear case of $609 and bull case of $2306. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 58/100.
REGN trades at a forward P/E ratio of 17.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 18.8x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
REGN appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $857.17 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
REGN analyst price targets range from $700 to $1057, a 42% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $857.17 consensus represents the middle ground. Our model's $609-$2306 range provides an independent fundamental perspective.